This study is testing whether a new oral medication called etavopivat can help people with sickle cell disease. It aims to increase healthy hemoglobin levels in the blood and reduce the frequency of painful vaso-occlusive crises. The trial involves 450 participants aged 12 to 65 …
Phase: PHASE3 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC